Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesA peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibodyStructure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological TheoryFine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesNovel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complexInducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingExploring peptide mimics for the production of antibodies against discontinuous protein epitopes.A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinEngineering filamentous phage carriers to improve focusing of antibody responses against peptides.Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine designAntibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitroAnti-idiotypic monobodies derived from a fibronectin scaffold.Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Phages and HIV-1: from display to interplay.Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.Anti-idiotypic monobodies for immune response profiling.Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.Back to the future: covalent epitope-based HIV vaccine development.Synthesis of a trimeric gp120 epitope mimic conjugated to a T-helper peptide to improve antigenicityArchitectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccinesGenetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaquesMultiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignCD4 binding determinant mimicry for HIV vaccine design.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designThe long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgGAntibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccineHuman immunodeficiency virus-1 vaccine design: where do we go now?Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
P2860
Q27489000-CB95C557-42EB-49B2-9199-8770E0C84037Q27649541-2136B34C-300E-4DB7-B2FA-6D2CA4C859A5Q27657585-BE447242-DB88-4D70-86D4-AA54D7FD39DEQ28071559-D15B8706-463A-410F-910F-01712C32BF27Q28217208-C443357E-446E-45CB-A2E1-B7FE71B957D5Q29619015-F0D55108-C224-41DE-B91F-A926A0E7F4BEQ30453272-4EB2FF4E-1346-4836-AD05-D0B0B6C0F2C8Q33392865-5FFC2E9E-514D-490D-9168-71D11757C178Q33520582-F2953FCC-7490-41B5-AD1D-9138488AAD77Q33522232-03576635-EB87-489F-9B0E-BADC1CAF3149Q33695321-5AF50CEB-513C-428C-9E41-DBB2A1A97943Q33717477-D1B65B86-0F92-45F2-8043-09589E48F9D7Q33743491-A67CA971-60E2-4416-8E54-946F63F1620DQ33853775-1078D7D3-0DDB-413C-BB05-E430E5EA6FC2Q33876210-0BD7B569-4992-4D68-9657-9625E7414E34Q34103170-1561F756-6933-400F-97B5-AB5CAC694771Q34225659-82A2FEF3-EEBF-427B-8DE1-EE14C7F61D8CQ34273397-4A96983A-2FF3-4B08-B580-9F88806BF497Q34332519-E6D89031-C2F5-46F6-A6B6-A0E13B9C3E7EQ34347058-C959CD03-38AC-4AFE-9B97-4C335718A092Q34543052-5A774B02-EC7B-4E20-B2AC-C5EC94B145C9Q34597300-ECB2007E-F7A1-4CC3-AB43-950095597B3DQ34709781-FC9FC01C-4CD0-4EF8-BBE2-2AB71B80423FQ34774808-DA93141D-B3CB-4549-9852-5A6D09C4FD7AQ34962907-12B0E741-19DB-4242-8B29-71F6EA380BD1Q35105006-13CDDC25-376B-40EE-A92B-C79736327164Q35943521-09264567-BFA2-44E3-88CB-A9A7FDC70D75Q35987717-8B56D4D5-23EE-4844-87D8-2BE7693EC578Q36016347-524BFC8B-207A-46A1-ABD2-C9306D092D12Q36447540-C81888BE-7CD4-474B-98D5-521CB69A3A38Q36469664-0EBB664F-B88A-4E58-B1AC-EA113F4D8B37Q36497712-9BCBB35D-7B05-4121-BB19-4062E84917A4Q36509423-888D84BD-5BF3-4D05-A23C-3774CD6963C0Q36600380-3105FDA4-32F7-4E4D-BA5D-FA6C6289386EQ36759899-D1318003-C71F-402B-9071-56ACD8C1F061Q37127735-EF40CA20-CA26-4FB1-9003-58E76058B9E3Q37801269-6C67B078-340C-457E-92FF-AC0FCC9282E0Q38695294-24B7B7F1-1F36-4243-9E18-81211AC7A4D2Q39430508-2E6C6AF7-E95C-4B9C-B650-2AECA814CFF6Q39748810-07856C77-811C-4BDB-8F78-95E336823BC9
P2860
Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Identification and characteriz ...... ency virus type 1 antibody b12
@ast
Identification and characteriz ...... ency virus type 1 antibody b12
@en
type
label
Identification and characteriz ...... ency virus type 1 antibody b12
@ast
Identification and characteriz ...... ency virus type 1 antibody b12
@en
prefLabel
Identification and characteriz ...... ency virus type 1 antibody b12
@ast
Identification and characteriz ...... ency virus type 1 antibody b12
@en
P2093
P2860
P1433
P1476
Identification and characteriz ...... ency virus type 1 antibody b12
@en
P2093
A Menendez
C F Barbas
D R Burton
L L Bonnycastle
M B Irving
P2860
P304
P356
10.1128/JVI.75.14.6692-6699.2001
P577
2001-07-01T00:00:00Z